Casdin Capital, LLC

Casdin Capital (Director) buys 200,000 WGS shares for $11.1M at blended $55.55 amid 69.7% decline from 52-week high

Casdin Capital executed two separate open-market purchases totaling 200,000 shares for $11,109,565.00 on consecutive days (June 4–5, 2026), increasing holdings to 3,707,164 shares from 3,507,164 shares. This accumulation occurs while the stock trades at $51.80, down 69.7% from its 52-week high of $170.87 but up 27.0% over the prior 30 days. The insider's prior trades at WGS show a 4-of-5 pattern of positive 90-day outcomes, most recently on May 18–20, 2026, each posting 19.2%–22.7% 90-day gains. GeneDx is unprofitable on a full-year basis (net income $-63,316,000.00) but generated $102,254,000.00 revenue last quarter with 40.0% annual growth, representing a loss-making but fast-growing enterprise. The timing of this 200,000-share purchase against recent operational scale and a severely depressed valuation relative to recent highs provides a data point on insider positioning in a volatile, unprofitable biotech name.

Casdin Capital (Director) purchased 500,000 shares over 3 days for $21,459,735.50 at blended $42.92, now -73.8% from 52-week high.

Casdin Capital executed three separate open-market purchases totaling 500,000 shares for $21,459,735.50 between May 18–20, 2026, increasing holdings from 3,007,164 to 3,507,164 shares (+16.6%). The purchases occurred at $42.55, $42.60, and $43.81, establishing a blended average of $42.92—yet the stock now trades at $44.73, still down 73.8% from its 52-week high of $170.87 and down 35.8% in 30 days. Within the SAME-TICKER HISTORY at WGS, prior timing patterns are favorable (4 of 5 prior trades well-timed at the 90-day mark), including four prior buys with 90-day returns of +41.9%, +53.4%, +67.8%, and +72.7%, though the most recent activity was a sell on 2025-08-22 that yielded only +7.2% and +10.9% returns. The company remains unprofitable with net income of $-63,316,000.00 against quarterly revenue of $102,254,000.00, despite 40.0% annual revenue growth. The substantial dollar commitment ($21.5M) and multi-day accumulation pattern against sharply depressed valuation (down 50.7% over 90 days) warrant close monitoring of fundamental inflection signals.

Casdin Capital sold 500,000 WGS shares at $120.90 for $60.5M, retaining 3.01M shares; stock at $128.66 (+55.1% in 30 days)

Casdin Capital, LLC, a director, executed a substantial sale of 500,000 shares (14.3% of prior holdings) at $120.90 on 2025-08-22, generating $60,451,950.00. This sale occurs during a sharp rally: the stock has appreciated +55.1% over the prior 30 days and +79.7% over 90 days, currently trading at $128.66, near its 52-week high. At the same ticker, Casdin's prior five trades (all buys in May–June 2024) posted strong 90-day returns (41.9% to 72.7%), and the insider demonstrated a 69.23% win rate across a cross-ticker track record of 13 prior buys. The sale represents a partial reduction rather than an exit, with the director retaining 3.01M shares post-transaction. Given the stock's recent momentum and the insider's historical track record of well-timed accumulation, the motivations for this sale—whether capital reallocation, liquidity needs, or a signal about valuation—warrant examination. The company reported revenue of $102,692,000.00 and quarterly net income of $10,809,000.00, though it was unprofitable on a full-year basis, with P/E at 2573.20 reflecting recent earnings volatility.